|
C6ORF130 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.58899999719497E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
6.92489999787327E-08 |
| Normal-vs-Stage2 |
2.229700E-02 |
| Normal-vs-Stage3 |
9.27540000028593E-07 |
| Normal-vs-Stage4 |
1.61180000457506E-08 |
| Stage1-vs-Stage2 |
4.444000E-02 |
| Stage1-vs-Stage3 |
7.806400E-01 |
| Stage1-vs-Stage4 |
1.328770E-01 |
| Stage2-vs-Stage3 |
5.849700E-02 |
| Stage2-vs-Stage4 |
1.081810E-02 |
| Stage3-vs-Stage4 |
2.917000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.32279999679008E-08 |
| Normal-vs-AfricanAmerican |
8.213100E-04 |
| Normal-vs-Asian |
5.59589999999943E-05 |
| Caucasian-vs-AfricanAmerican |
7.451000E-01 |
| Caucasian-vs-Asian |
5.559800E-01 |
| AfricanAmerican-vs-Asian |
9.142400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.34020000003488E-06 |
| Normal-vs-Female |
3.20199999848114E-08 |
| Male-vs-Female |
7.027000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.08500000492751E-09 |
| Normal-vs-Age(41-60Yrs) |
3.81360000000219E-05 |
| Normal-vs-Age(61-80Yrs) |
1.27800000004896E-06 |
| Normal-vs-Age(81-100Yrs) |
3.305900E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.874260E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.390400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.272600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.840200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.954400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.563200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.737210E-01 |
| Classical-VS-Follicular |
1.966070E-02 |
| Classical-VS-Other |
8.956400E-01 |
| Classical-VS-Normal |
7.01409996750613E-09 |
| Tall-VS-Follicular |
2.862800E-03 |
| Tall-VS-Other |
7.127400E-01 |
| Tall-VS-Normal |
2.0039000003802E-07 |
| Follicular-VS-Other |
4.124000E-01 |
| Follicular-VS-Normal |
6.464200E-03 |
| Other-VS-Normal |
2.452000E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
7.54430000000639E-05 |
| Normal-vs-N1 |
3.26438875930535E-12 |
| N0-vs-N1 |
2.03850000002337E-06 |
|
|
